Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
30.07 USD +2.59% Intraday chart for Supernus Pharmaceuticals, Inc. +2.28% +3.90%
04-08 Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready DJ
04-08 Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket MT

Business Summary

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Number of employees: 652

Sales per Business

USD in Million2022Weight2023Weight Delta
Treatment of Central Nervous System Diseases
100.0 %
667 100.0 % 608 100.0 % -8.95%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
667 100.0 % 608 100.0 % -8.95%

Managers

Managers TitleAgeSince
Jack Khattar FOU
 Founder 62 29/03/05
Timothy Dec DFI
 Director of Finance/CFO 66 22/08/21
Frank Mottola CTO
 Chief Tech/Sci/R&D Officer 52 31/12/04
Jonathan Rubin CTO
 Chief Tech/Sci/R&D Officer 62 31/01/20
Padmanabh P. Bhatt CTO
 Chief Tech/Sci/R&D Officer 66 29/03/05
Kevin T. Anderson CMP
 Compliance Officer 61 31/12/11
Taylor Raiford SAM
 Sales & Marketing - 31/12/14
Todd Horich SAM
 Sales & Marketing - 30/05/18
Bryan A. Roecklein PRN
 Corporate Officer/Principal - 30/06/15
Tami Martin LAW
 General Counsel 68 31/12/07

Members of the board

Members of the board TitleAgeSince
Georges Gemayel BRD
 Director/Board Member 64 22/03/15
Charles Newhall CHM
 Chairman 79 29/03/05
John Siebert BRD
 Director/Board Member 84 31/12/10
Frederick Hudson BRD
 Director/Board Member 78 15/11/10
Carrolee Barlow BRD
 Director/Board Member 60 26/06/18
Jack Khattar FOU
 Founder 62 29/03/05
Bethany Sensenig BRD
 Director/Board Member 48 20/08/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 54,734,956 51,934,710 ( 94.88 %) 0 94.88 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
17.98 %
9,841,300 17.98 % 336 M $
Vanguard Fiduciary Trust Co.
11.35 %
6,214,731 11.35 % 212 M $
Armistice Capital LLC
8.495 %
4,650,000 8.495 % 159 M $
Macquarie Investment Management Business Trust
5.002 %
2,737,716 5.002 % 93 M $
Dimensional Fund Advisors LP
4.488 %
2,456,369 4.488 % 84 M $
STATE STREET CORPORATION
3.768 %
2,062,326 3.768 % 70 M $
POLAR CAPITAL HOLDINGS PLC
3.543 %
1,939,365 3.543 % 66 M $
Jack Khattar
3.540 %
1,937,667 3.540 % 66 M $
Stephens Investment Management Group LLC
3.480 %
1,904,864 3.480 % 65 M $
BNY Mellon Investment Adviser, Inc.
3.180 %
1,740,486 3.180 % 59 M $

Company contact information

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue

20850, Rockville

+301 838 2500

http://www.supernus.com
address Supernus Pharmaceuticals, Inc.(SUPN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
30.07 USD
Average target price
40.33 USD
Spread / Average Target
+34.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
INDIVIOR PLC Stock Indivior PLC
+18.82% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. Company Supernus Pharmaceuticals, Inc.